Epigenomes as therapeutic targets

Pharmacology and Therapeutics

Volumn 151, Issue , 2015, Pages 72-86

  Hamm, Christopher A ^a   Costa, Fabricio F ^a,b,c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b StartUp Health Academy   (United States)

^c Genomic Enterprise   (United States)

^d UCB PHARMA   (Belgium)

Author keywords

Complex Diseases; DNA Methylation; Epigenetics; Epigenomes; Histone Modifications; Therapeutics

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; DNA; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; UNTRANSLATED RNA; ANTINEOPLASTIC AGENT; CYTIDINE DEAMINASE; HISTONE; HISTONE DEACETYLASE INHIBITOR;

ARTICLE; CHROMATIN; CLINICAL MEDICINE; CPG ISLAND; DEVELOPMENT; DNA METHYLATION; DNA SEQUENCE; DRUG DELIVERY SYSTEM; DRUG TARGETING; EMBRYO DEVELOPMENT; EPIGENETICS; MEDICAL RESEARCH; NUCLEOSOME; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DISEASES; GENETIC EPIGENESIS; GENETICS; HUMAN; HUMAN GENOME; IMMUNOTHERAPY; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CPG ISLANDS; CYTIDINE DEAMINASE; DISEASE; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENOME, HUMAN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNOTHERAPY; SIGNAL TRANSDUCTION;

EID: 84930091174     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.03.003     Document Type: Review

References (132)

1. B. Alberts, J. A., J. Lewis, M. Raff, K. Roberts, and P. Walter Molecular biology of the cell 4th ed. Garland Sci 2002
2. L. Alland, R. Muhle, H. Hou Jr., J. Potes, L. Chin, N. Schreiber-Agus, and R.A. DePinho Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression Nature 387 1997 49 55
3. A. Annunziato DNA packaging: Nucleosomes and chromatin Nat Educ 2008 (nature.co006D)
4. S. Asgatay, C. Champion, G. Marloie, T. Drujon, C. Senamaud-Beaufort, A. Ceccaldi, A. Erdmann, A. Rajavelu, P. Schambel, A. Jeltsch, O. Lequin, P. Karoyan, P.B. Arimondo, and D. Guianvarc'h Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1 J Med Chem 57 2014 421 434
5. N. Azad, C.A. Zahnow, C.M. Rudin, and S.B. Baylin The future of epigenetic therapy in solid tumours - Lessons from the past Nat Rev Clin Oncol 10 2013 256 266
6. C. Balch, and K.P. Nephew Epigenetic targeting therapies to overcome chemotherapy resistance Adv Exp Med Biol 754 2013 285 311
7. J. Bauman, C. Verschraegen, S. Belinsky, C. Muller, T. Rutledge, M. Fekrazad, M. Ravindranathan, S.J. Lee, and D. Jones A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies Cancer Chemother Pharmacol 69 2012 547 554
8. Y. Bergman, and H. Cedar DNA methylation dynamics in health and disease Nat Struct Mol Biol 20 2013 274 281
9. J.H. Beumer, J.L. Eiseman, R.A. Parise, E. Joseph, J.L. Holleran, J.M. Covey, and M.J. Egorin Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice Clin Cancer Res 12 2006 7483 7491
10. J.H. Beumer, R.A. Parise, E.M. Newman, J.H. Doroshow, T.W. Synold, H.J. Lenz, and M.J. Egorin Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU) Cancer Chemother Pharmacol 62 2008 363 368
11. Bionor-Pharma First evidence that romidepsin "kicks" HIV out of reservoirs See more at: http://www.bionorpharma.com/First+Evidence+that+Romidepsin+%E2%80%9CKicks%E2%80%9D+HIV+out+of+Reservoirs.b7C-wlvYWU.ips#sthash.niStZLPd.dpuf 2014 (Bionor Pharma)
12. A. Bird DNA methylation patterns and epigenetic memory Genes Dev 16 2002 6 21
13. G. Borthakur, S.E. Ahdab, F. Ravandi, S. Faderl, A. Ferrajoli, B. Newman, J.P. Issa, and H. Kantarjian Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine Leuk Lymphoma 49 2008 690 695
14. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, H.C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T.M. Salay, S. Alaparthy, J.F. Grosso, A.J. Korman, S.M. Parker, S. Agrawal, S.M. Goldberg, D.M. Pardoll, A. Gupta, and J.M. Wigginton Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
15. J.E. Brownell, J. Zhou, T. Ranalli, R. Kobayashi, D.G. Edmondson, S.Y. Roth, and C.D. Allis Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation Cell 84 1996 843 851
16. I. Cantone, and A.G. Fisher Epigenetic programming and reprogramming during development Nat Struct Mol Biol 20 2013 282 289
17. C.J. Chang, and M.C. Hung The role of EZH2 in tumour progression Br J Cancer 106 2012 243 247
18. A. Chatagnon, L. Perriaud, N. Nazaret, S. Croze, J. Benhattar, J. Lachuer, and R. Dante Preferential binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions Epigenetics 6 2011 1295 1307
19. X. Cheng, and R.M. Blumenthal Coordinated chromatin control: Structural and functional linkage of DNA and histone methylation Biochemistry 49 2010 2999 3008
20. N. Chia TET inhibitors as potential new cancer drugs - An enzyme that converts 5-methylcytosine to 5-hydroxymethylcytosine Int Drug Discov? Vol. 2014 2012
21. S. Cocozza, M.M. Akhtar, G. Miele, and A. Monticelli CpG islands undermethylation in human genomic regions under selective pressure PLoS ONE 6 2011 e23156
22. F. Coppede The potential of epigenetic therapies in neurodegenerative diseases Front Genet 5 2014 220
23. N. Coppieters, B.V. Dieriks, C. Lill, R.L. Faull, M.A. Curtis, and M. Dragunow Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain Neurobiol Aging 6 2013 1334 1344
24. S. Coral, G. Parisi, H.J. Nicolay, F. Colizzi, R. Danielli, E. Fratta, A. Covre, P. Taverna, L. Sigalotti, and M. Maio Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide Cancer Immunol Immunother 62 2013 605 614
25. F.F. Costa Non-coding RNAs, epigenetics and complexity Gene 410 2008 9 17
26. F.F. Costa Epigenomics in cancer management Cancer Manag Res 2 2010 255 265
27. F.F. Costa, K. Le Blanc, and B. Brodin Concise review: Cancer/testis antigens, stem cells, and cancer Stem Cells 25 2007 707 711
28. F. Crea, L. Fornaro, G. Bocci, L. Sun, W.L. Farrar, A. Falcone, and R. Danesi EZH2 inhibition: Targeting the crossroad of tumor invasion and angiogenesis Cancer Metastasis Rev 31 2012 753 761
29. B. Delatte, and F. Fuks TET proteins: On the frenetic hunt for new cytosine modifications Brief Funct Genomics 12 2013 191 204
30. J.E. Dodge, M. Okano, F. Dick, N. Tsujimoto, T. Chen, S. Wang, Y. Ueda, N. Dyson, and E. Li Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization J Biol Chem 280 2005 17986 17991
31. M. Dokmanovic, C. Clarke, and P.A. Marks Histone deacetylase inhibitors: Overview and perspectives Mol Cancer Res 5 2007 981 989
32. A. Eden, F. Gaudet, A. Waghmare, and R. Jaenisch Chromosomal instability and tumors promoted by DNA hypomethylation Science 300 2003 455
33. A.P. Feinberg Phenotypic plasticity and the epigenetics of human disease Nature 447 2007 433 440
34. A.P. Feinberg, and B. Tycko The history of cancer epigenetics Nat Rev Cancer 4 2004 143 153
35. A.F. Fernandez, C. Huidobro, and M.F. Fraga De novo DNA methyltransferases: Oncogenes, tumor suppressors, or both? Trends Genet 28 2012 474 479
36. C.L. Fisher, and A.G. Fisher Chromatin states in pluripotent, differentiated, and reprogrammed cells Curr Opin Genet Dev 21 2011 140 146
37. E. Flatau, F.A. Gonzales, L.A. Michalowsky, and P.A. Jones DNA methylation in 5-aza-2′-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells Mol Cell Biol 4 1984 2098 2102
38. F. Gaudet, J.G. Hodgson, A. Eden, L. Jackson-Grusby, J. Dausman, J.W. Gray, H. Leonhardt, and R. Jaenisch Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
39. M.A. Glozak, N. Sengupta, X. Zhang, and E. Seto Acetylation and deacetylation of non-histone proteins Gene 363 2005 15 23
40. V. Greger, E. Passarge, W. Hopping, E. Messmer, and B. Horsthemke Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma Hum Genet 83 1989 155 158
41. B. Groselj, N.L. Sharma, F.C. Hamdy, M. Kerr, and A.E. Kiltie Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair Br J Cancer 108 2013 748 754
42. J.A. Hackett, R. Sengupta, J.J. Zylicz, K. Murakami, C. Lee, T.A. Down, and M.A. Surani Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine Science 339 2013 448 452
43. C.A. Hamm, and F.F. Costa The impact of epigenomics on future drug design and new therapies Drug Discov Today 16 2011 626 635
44. A.H. Hassan, P. Prochasson, K.E. Neely, S.C. Galasinski, M. Chandy, M.J. Carrozza, and J.L. Workman Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes Cell 111 2002 369 379
45. Y.F. He, B.Z. Li, Z. Li, P. Liu, Y. Wang, Q. Tang, J. Ding, Y. Jia, Z. Chen, L. Li, Y. Sun, X. Li, Q. Dai, C.X. Song, K. Zhang, C. He, and G.L. Xu Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA Science 333 2011 1303 1307
46. T.R. Hebbes, A.W. Thorne, and C. Crane-Robinson A direct link between core histone acetylation and transcriptionally active chromatin EMBO J 7 1988 1395 1402
47. P.W. Hollenbach, A.N. Nguyen, H. Brady, M. Williams, Y. Ning, N. Richard, L. Krushel, S.L. Aukerman, C. Heise, and K.J. MacBeth A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines PLoS ONE 5 2010 e9001
48. R.S. Illingworth, U. Gruenewald-Schneider, S. Webb, A.R. Kerr, K.D. James, D.J. Turner, C. Smith, D.J. Harrison, R. Andrews, and A.P. Bird Orphan CpG islands identify numerous conserved promoters in the mammalian genome PLoS Genet 6 2010 e1001134
49. T. Isobe, S.N. Song, P. Tiwari, H. Ito, Y. Yamaguchi, and K. Yoshizaki Activation-induced cytidine deaminase auto-activates and triggers aberrant gene expression FEBS Lett 587 2013 2487 2492
50. J.P. Issa Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed/refractory acute myeloid leukemia European Cancer Congress 2013 (Amsterdam Netherlands)
51. J.P. Issa First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Am Soc Hematol 2013 http://astx.com/content/resources/2013-SGI-110-Oral-ASH-abst-497-Kantarjian-final2.pdf
52. J.P. Issa, and H.M. Kantarjian Targeting DNA methylation Clin Cancer Res 15 2009 3938 3946
53. S. Ito, A.C. D'Alessio, O.V. Taranova, K. Hong, L.C. Sowers, and Y. Zhang Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification Nature 466 2010 1129 1133
54. M. Iurlaro, G. Ficz, D. Oxley, E.A. Raiber, M. Bachman, M.J. Booth, S. Andrews, S. Balasubramanian, and W. Reik A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation Genome Biol 14 2013 R119
55. F. Jawert, B. Hasseus, G. Kjeller, B. Magnusson, L. Sand, and L. Larsson Loss of 5-hydroxymethylcytosine and TET2 in oral squamous cell carcinoma Anticancer Res 33 2013 4325 4328
56. S. Jayaraman Novel methods of type 1 diabetes treatment Discov Med 17 2014 347 355
57. M. Jeong, D. Sun, M. Luo, Y. Huang, G.A. Challen, B. Rodriguez, X. Zhang, L. Chavez, H. Wang, R. Hannah, S.B. Kim, L. Yang, M. Ko, R. Chen, B. Gottgens, J.S. Lee, P. Gunaratne, L.A. Godley, G.J. Darlington, A. Rao, W. Li, and M.A. Goodell Large conserved domains of low DNA methylation maintained by Dnmt3a Nat Genet 46 2014 17 23
58. P.A. Jones Functions of DNA methylation: Islands, start sites, gene bodies and beyond Nat Rev Genet 13 2012 484 492
59. P.A. Jones Priming cancer therapies with epigenetics with Dr. Peter Jones 2013 (Epigenie.com)
60. P.A. Jones, and S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415 428
61. J. Jurkin, G. Zupkovitz, S. Lagger, R. Grausenburger, A. Hagelkruys, L. Kenner, and C. Seiser Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis Cell Cycle 10 2011 406 412
62. R.Z. Jurkowska, T.P. Jurkowski, and A. Jeltsch Structure and function of mammalian DNA methyltransferases Chembiochem 12 2011 206 222
63. M.F. Kaiser, D.C. Johnson, P. Wu, B.A. Walker, A. Brioli, F. Mirabella, C.P. Wardell, L. Melchor, F.E. Davies, and G.J. Morgan Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma Blood 122 2013 219 226
64. E. Kaminskas, A.T. Farrell, Y.C. Wang, R. Sridhara, and R. Pazdur FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension Oncologist 10 2005 176 182
65. H.M. Kantarjian, X.G. Thomas, A. Dmoszynska, A. Wierzbowska, G. Mazur, J. Mayer, J.P. Gau, W.C. Chou, R. Buckstein, J. Cermak, C.Y. Kuo, A. Oriol, F. Ravandi, S. Faderl, J. Delaunay, D. Lysak, M. Minden, and C. Arthur Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia J Clin Oncol 30 2012 2670 2677
66. Kantarjian, H. M. E. E. (2013). Drug Approvals in Acute Myeloid Leukemia: Can We Do Better?. The ASCO Post, 4.
67. A.R. Karpf A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy Epigenetics 1 2006 116 120
68. R.D. Kelly, and S.M. Cowley The physiological roles of histone deacetylase (HDAC) 1 and 2: Complex co-stars with multiple leading parts Biochem Soc Trans 41 2013 741 749
69. S.N. Khan, and A.U. Khan Role of histone acetylation in cell physiology and diseases: An update Clin Chim Acta 411 2010 1401 1411
70. E. Laille, M.R. Savona, B.L. Scott, T.E. Boyd, Q. Dong, and B. Skikne Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies J Clin Pharmacol 54 2014 630 639
71. L. Laurent, E. Wong, G. Li, T. Huynh, A. Tsirigos, C.T. Ong, H.M. Low, K.W. Kin Sung, I. Rigoutsos, J. Loring, and C.L. Wei Dynamic changes in the human methylome during differentiation Genome Res 20 2010 320 331
72. E. Li, T.H. Bestor, and R. Jaenisch Targeted mutation of the DNA methyltransferase gene results in embryonic lethality Cell 69 1992 915 926
73. L.H. Li, E.J. Olin, H.H. Buskirk, and L.M. Reineke Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia Cancer Res 30 1970 2760 2769
74. C.G. Lian, Y. Xu, C. Ceol, F. Wu, A. Larson, K. Dresser, W. Xu, L. Tan, Y. Hu, Q. Zhan, C.W. Lee, D. Hu, B.Q. Lian, S. Kleffel, Y. Yang, J. Neiswender, A.J. Khorasani, R. Fang, C. Lezcano, L.M. Duncan, R.A. Scolyer, J.F. Thompson, H. Kakavand, Y. Houvras, L.I. Zon, M.C. Mihm Jr., U.B. Kaiser, T. Schatton, B.A. Woda, G.F. Murphy, and Y.G. Shi Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma Cell 150 2012 1135 1146
75. R. Lister, M. Pelizzola, R.H. Dowen, R.D. Hawkins, G. Hon, J. Tonti-Filippini, J.R. Nery, L. Lee, Z. Ye, Q.M. Ngo, L. Edsall, J. Antosiewicz-Bourget, R. Stewart, V. Ruotti, A.H. Millar, J.A. Thomson, B. Ren, and J.R. Ecker Human DNA methylomes at base resolution show widespread epigenomic differences Nature 462 2009 315 322
76. C. Liu, L. Liu, X. Chen, J. Shen, J. Shan, Y. Xu, Z. Yang, L. Wu, F. Xia, P. Bie, Y. Cui, X.W. Bian, and C. Qian Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1 PLoS ONE 8 2013 e62828
77. D. Matei, F. Fang, C. Shen, J. Schilder, A. Arnold, Y. Zeng, W.A. Berry, T. Huang, and K.P. Nephew Epigenetic resensitization to platinum in ovarian cancer Cancer Res 72 2012 2197 2205
78. M. Mellen, P. Ayata, S. Dewell, S. Kriaucionis, and N. Heintz MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system Cell 151 2012 1417 1430
79. K.H. Metzeler, A. Walker, S. Geyer, R. Garzon, R.B. Klisovic, C.D. Bloomfield, W. Blum, and G. Marcucci DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia Leukemia 26 2012 1106 1107
80. T.B. Miranda, and P.A. Jones DNA methylation: The nuts and bolts of repression J Cell Physiol 213 2007 384 390
81. C.A. Mizzen, X.J. Yang, T. Kokubo, J.E. Brownell, A.J. Bannister, T. Owen-Hughes, J. Workman, L. Wang, S.L. Berger, T. Kouzarides, Y. Nakatani, and C.D. Allis The TAF(II)250 subunit of TFIID has histone acetyltransferase activity Cell 87 1996 1261 1270
82. D.P. Munoz, E.L. Lee, S. Takayama, J.P. Coppe, S.J. Heo, D. Boffelli, J.M. Di Noia, and D.I. Martin Activation-induced cytidine deaminase (AID) is necessary for the epithelial-mesenchymal transition in mammary epithelial cells Proc Natl Acad Sci U S A 110 2013 E2977 E2986
83. M. Munzel, D. Globisch, and T. Carell 5-hydroxymethylcytosine, the sixth base of the genome Angew Chem Int Ed Engl 50 2011 6460 6468
84. M. Muramatsu, K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme Cell 102 2000 553 563
85. K. Odunsi, J. Matsuzaki, S.R. James, P. Mhawech-Fauceglia, T. Tsuji, A. Miller, W. Zhang, S.N. Akers, E.A. Griffiths, A. Miliotto, A. Beck, C.A. Batt, G. Ritter, S. Lele, S. Gnjatic, and A.R. Karpf Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer Cancer Immunol Res 2 2014 37 49
86. M. Okano, D.W. Bell, D.A. Haber, and E. Li DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development Cell 99 1999 247 257
87. M. Okano, S. Xie, and E. Li Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases Nat Genet 19 1998 219 220
88. I.M. Okazaki, A. Kotani, and T. Honjo Role of AID in tumorigenesis Adv Immunol 94 2007 245 273
89. B.A. Orr, M.C. Haffner, W.G. Nelson, S. Yegnasubramanian, and C.G. Eberhart Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma PLoS ONE 7 2012 e41036
90. M. Pertea, and S.L. Salzberg Between a chicken and a grape: Estimating the number of human genes Genome Biol 11 2010 206
91. S.L. Peters, R.A. Hlady, J. Opavska, D. Klinkebiel, S. Novakova, L.M. Smith, R.E. Lewis, A.R. Karpf, M.A. Simpson, L. Wu, and R. Opavsky Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas Mol Cell Biol 33 2013 4321 4333
92. F.M. Piccolo, and A.G. Fisher Getting rid of DNA methylation Trends Cell Biol 24 2014 136 143
93. I.P. Pogribny, and F.A. Beland DNA hypomethylation in the origin and pathogenesis of human diseases Cell Mol Life Sci 66 2009 2249 2261
94. A. Portela, and M. Esteller Epigenetic modifications and human disease Nat Biotechnol 28 2010 1057 1068
95. S. Pradhan, A. Bacolla, R.D. Wells, and R.J. Roberts Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation J Biol Chem 274 1999 33002 33010
96. T. Qin, J. Jelinek, J. Si, J. Shu, and J.P. Issa Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines Blood 113 2009 659 667
97. B.H. Ramsahoye, D. Biniszkiewicz, F. Lyko, V. Clark, A.P. Bird, and R. Jaenisch Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a Proc Natl Acad Sci U S A 97 2000 5237 5242
98. D. Ray-Gallet, and G. Almouzni Nucleosome dynamics and histone variants Essays Biochem 48 2010 75 87
99. W. Reik, W. Dean, and J. Walter Epigenetic reprogramming in mammalian development Science 293 2001 1089 1093
100. S. Reither, F. Li, H. Gowher, and A. Jeltsch Catalytic mechanism of DNA-(cytosine-C5)-methyltransferases revisited: covalent intermediate formation is not essential for methyl group transfer by the murine Dnmt3a enzyme J Mol Biol 329 2003 675 684
101. J. Ren, B.N. Singh, Q. Huang, Z. Li, Y. Gao, P. Mishra, Y.L. Hwa, J. Li, S.C. Dowdy, and S.W. Jiang DNA hypermethylation as a chemotherapy target Cell Signal 23 2011 1082 1093
102. V. Rishi, P. Bhattacharya, R. Chatterjee, J. Rozenberg, J. Zhao, K. Glass, P. Fitzgerald, and C. Vinson CpG methylation of half-CRE sequences creates C/EBP alpha binding sites that activate some tissue-specific genes Proc Natl Acad Sci U S A 107 2010 20311 20316
103. K.D. Robertson, E. Uzvolgyi, G. Liang, C. Talmadge, J. Sumegi, F.A. Gonzales, and P.A. Jones The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors Nucleic Acids Res 27 1999 2291 2298
104. R. Robinson An HDAC in the cytoplasm, not the nucleus, plays a pathogenic role in Huntington's disease PLoS Biol 11 2013 e1001718
105. S.G. Royce, and T.C. Karagiannis Histone deacetylases and their inhibitors: New implications for asthma and chronic respiratory conditions Curr Opin Allergy Clin Immunol 14 2014 44 48
106. R. Sanchez, and M.M. Zhou The role of human bromodomains in chromatin biology and gene transcription Curr Opin Drug Discov Devel 12 2009 659 665
107. J. Sandoval, and M. Esteller Cancer epigenomics: Beyond genomics Curr Opin Genet Dev 22 2012 50 55
108. F. Santos, B. Hendrich, W. Reik, and W. Dean Dynamic reprogramming of DNA methylation in the early mouse embryo Dev Biol 241 2002 172 182
109. M. Schaefer, and F. Lyko Solving the Dnmt2 enigma Chromosoma 119 2010 35 40
110. C. Stresemann, and F. Lyko Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine Int J Cancer 123 2008 8 13
111. K. Struhl Histone acetylation and transcriptional regulatory mechanisms Genes Dev 12 1998 599 606
112. M. Tahiliani, K.P. Koh, Y. Shen, W.A. Pastor, H. Bandukwala, Y. Brudno, S. Agarwal, L.M. Iyer, D.R. Liu, L. Aravind, and A. Rao Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 324 2009 930 935
113. H. Tao, K.H. Shi, J.J. Yang, C. Huang, H.Y. Zhan, and J. Li Histone deacetylases in cardiac fibrosis: Current perspectives for therapy Cell Signal 26 2014 521 527
114. C.S. Tellez, M.J. Grimes, M.A. Picchi, Y. Liu, T.H. March, M.D. Reed, A. Oganesian, P. Taverna, and S.A. Belinsky SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome Int J Cancer 135 9 2014 2223 2231
115. N.A. Temiz, D.E. Donohue, A. Bacolla, B.T. Luke, and J.R. Collins The role of methylation in the intrinsic dynamics of B- and Z-DNA PLoS ONE 7 2012 e35558
116. C.H. Waddington An introduction to modern genetics 1939 New York, The Macmillan Company New York
117. D.G. Wei, V. Chiang, E. Fyne, M. Balakrishnan, T. Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J.P. Murry, G. Stepan, K.M. Stray, A. Tsai, H. Yu, J. Spindler, M. Kearney, C.A. Spina, D. McMahon, J. Lalezari, D. Sloan, J. Mellors, R. Geleziunas, and T. Cihlar Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing PLoS Pathog 10 2014 e1004071
118. A.P. Wolffe, and M.A. Matzke Epigenetics: Regulation through repression Science 286 1999 481 486
119. C.L. Woodcock, and R.P. Ghosh Chromatin higher-order structure and dynamics Cold Spring Harb Perspect Biol 2 2010 a000596
120. J. Wrangle, W. Wang, A. Koch, H. Easwaran, H.P. Mohammad, F. Vendetti, W. Vancriekinge, T. Demeyer, Z. Du, P. Parsana, K. Rodgers, R.W. Yen, C.A. Zahnow, J.M. Taube, J.R. Brahmer, S.S. Tykodi, K. Easton, R.D. Carvajal, P.A. Jones, P.W. Laird, D.J. Weisenberger, S. Tsai, R.A. Juergens, S.L. Topalian, C.M. Rudin, M.V. Brock, D. Pardoll, and S.B. Baylin Alterations of immune response of non-small cell lung cancer with azacytidine Oncotarget 4 2013 2067 2079
121. J. Wright Epigenetics: Reversible tags Nature 498 2013 S10 S11
122. H. Wu, A.C. D'Alessio, S. Ito, K. Xia, Z. Wang, K. Cui, K. Zhao, Y.E. Sun, and Y. Zhang Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells Nature 473 2011 389 393
123. J. Yan, J.R. Zierath, and R. Barres Evidence for non-CpG methylation in mammals Exp Cell Res 317 2011 2555 2561
124. H. Yang, Y. Liu, F. Bai, J.Y. Zhang, S.H. Ma, J. Liu, Z.D. Xu, H.G. Zhu, Z.Q. Ling, D. Ye, K.L. Guan, and Y. Xiong Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation Oncogene 32 2013 663 669
125. X. Yang, F. Lay, H. Han, and P.A. Jones Targeting DNA methylation for epigenetic therapy Trends Pharmacol Sci 31 2010 536 546
126. X.J. Yang, and E. Seto HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention Oncogene 26 2007 5310 5318
127. Y.L. Yao, and W.M. Yang Beyond histone and deacetylase: An overview of cytoplasmic histone deacetylases and their nonhistone substrates J Biomed Biotechnol 2011 2011 146493
128. C. Ye, and L. Li 5-hydroxymethylcytosine: A new insight into epigenetics in cancer Cancer Biol Ther 15 2013
129. C.B. Yoo, S. Jeong, G. Egger, G. Liang, P. Phiasivongsa, C. Tang, S. Redkar, and P.A. Jones Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides Cancer Res 67 2007 6400 6408
130. C.B. Yoo, and P.A. Jones Epigenetic therapy of cancer: Past, present and future Nat Rev Drug Discov 5 2006 37 50
131. J. Yoo, S. Choi, and J.L. Medina-Franco Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: Implications for the mechanism of inhibition of DNMTs PLoS ONE 8 2013 e62152
132. Q. Zhao, J. Fan, W. Hong, L. Li, and M. Wu Inhibition of cancer cell proliferation by 5-fluoro-2′-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway Springerplus 1 2012 65